Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 18;9:14960. doi: 10.1038/s41598-019-51530-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Logan graphical analysis of [⁶⁸Ga]Ga-DO3A-S01-GCG binding. Logan derived V_t in the liver and spleen plotted against co-injected DO3A-S01-GCG peptide mass dose (A), where the green dotted line indicates <5% occupancy i.e. negligible mass effect, the blue dotted line indicates in vivo K_d, the red _dotted line indicates the background. Co-injected peptide doses >5 µg/kg strongly and consistently decreased the liver binding of [⁶⁸Ga]Ga-DO3A-S01-GCG compared to administration of doses with negligible mass effect. (B) Occupancy incurred by co-injected amount of DO3A-S01-GCG peptide mass dose. (C) Correlation between Logan derived V_t and SUV_90min in the liver (D). ****Indicates p < 0.0001. Test-retest variability of [⁶⁸Ga]Ga-DO3A-S01-GCG binding in the liver over the course of an experimental day. (E) Effect on [⁶⁸Ga]Ga-DO3A-S01-GCG binding in the liver by pre-treatment with 30 µg/kg of the acylated GCGR agonist 1-GCG (F).